Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details Textual)

v3.5.0.2
License Agreements (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2016
May 31, 2016
Sep. 30, 2015
May 31, 2015
Mar. 31, 2015
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Dec. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Stock Issued During Period, Value, Issued for Services               $ 14,000    
Proceeds from Issuance of Common Stock               570,000 $ 11,068,000  
Clinical Development Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due $ 7,000,000         $ 7,000,000   7,000,000    
Commercial Sales In Specified Territories [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due 14,500,000         14,500,000   14,500,000    
Neupharma [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Payment Of Upfront Fees         $ 1,000,000          
Reimbursement Of Cost Recognized As Revenue           251,000   732,000    
Payment For Non refundable Milestone payments 1,000,000                  
Neupharma [Member] | Additional Sales Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
License Expense       $ 22,500,000            
Neupharma [Member] | Clinical Development Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
License Expense       40,000,000            
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
License Expense       $ 40,000,000            
Dana-Farber [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Shares Issued, Price Per Share       $ 0.065            
Payments for Other Fees         $ 1,000,000          
Stock Issued During Period, Shares, Issued for Services     136,830 500,000            
Stock Issued During Period, Value, Issued for Services     $ 600,000 $ 32,500            
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners       5.00%            
Proceeds from Issuance of Common Stock     $ 10,000,000              
Dana-Farber [Member] | First Commercial Sale Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due 21,500,000         21,500,000   21,500,000    
Maximum Potential Milestone Payments 21,500,000         21,500,000   21,500,000    
Dana-Farber [Member] | Additional Sales Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due 60,000,000         60,000,000   60,000,000    
Maximum Potential Milestone Payments $ 60,000,000         60,000,000   60,000,000    
Teva Pharmaceutical Industries Ltd [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Payment Of Upfront Fees                   $ 500,000
Teva Pharmaceutical Industries Ltd [Member] | Clinical Development Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
License Expense                   206,500,000
Teva Pharmaceutical Industries Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
License Expense                   $ 220,000,000
Jubilant Biosys Ltd [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Payments for Other Fees   $ 1,000,000                
Payment Of Upfront Fees   2,000,000                
Revenue Recognition Milestone Method, Payments Due   $ 87,500,000                
Operating Leases, Income Statement, Sublease Revenue           300,000   1,300,000    
Research and Development Cost, Shared Percentage   50.00%                
Jubilant Biosys Ltd [Member] | Clinical Development Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
License Expense   $ 89,000,000                
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
License Expense   59,500,000                
Jubilant Biosys Ltd [Member] | Successful Achievement Of One Preclinical Milestone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due   300,000                
Jubilant Biosys Ltd [Member] | Completion Of Three Clinical Development Milestones For Two Licensed Products [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due   25,500,000                
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due   61,700,000                
Jubilant Biosys Ltd [Member] | Three Sales Milestones Based On Aggregate Net Sales [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition Milestone Method, Payments Due   89,000,000                
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
License Expense   $ 89,000,000                
Collaboration Agreement With TGTX [Member]                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Revenue Recognition, Milestone Method, Revenue Recognized           $ 0 $ 25,000 $ 20,000 $ 500,000